Eosinophilic Asthma Resource Centre
Educational platform focused on providing education in the pulmonology community and beyond
Efficacy and safety of dupilumab as add-on therapy
Commentary by Dr. William W. Busse
Sally Wenzel and colleagues presented the findings of a large phase 2b study that evaluated the effects of dupilumab, an IL-4/IL-13 receptor antagonist, in patients with severe asthma. Earlier studies with dupilumab had shown that the administration of this monoclonal antibody allowed for the successful reduction of concomitant use of inhaled corticosteroids and long-acting beta-agonists without loss of asthma control and suggested that this particular monoclonal antibody may provide additional benefit for severe asthma patients with uncontrolled asthma despite optimal therapy with …
Commentary by Dr. William W. BusseSally Wenzel and colleagues presented the findings of a large phase 2b study that evaluated the effects of dupilumab, an...
Anna von Bülow, Vibeke Backer, Uffe Bodtger, Niels Ulrik Søes-Petersen, Karin Dahl Assing, Tina Skjold, Celeste Porsbjerg
Respiratory Medicine, March 2017, Pages 21 - 29
Heterogeneity of obesity-asthma association disentangled by latent class analysis, the SAPALDIA cohort
Ayoung Jeong, Medea Imboden, Sofie Hansen, Elisabeth Zemp, Pierre-Olivier Bridevaux, Gianfranco Lovison, Christian Schindler, Nicole Probst-Hensch
Respiratory Medicine, April 2017, Pages 25 - 32
Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity
Malinovschi A, Janson C, Borres M, Alving KJ Allergy Clin Immunol. 2016; Volume 138, Issue 5, November 2016, Pages 1301-1308.e2
Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils
Walsh CJ, Zaihra T, Benedetti A, Fugère C, Olivenstein R, Lemière C, Hamid Q, Martin JGClin Exp Allergy. 2016 Oct;46(10):1291-302. doi: 10.1111/cea.12762. Epub 2016 Jun 27.
This online resource center has been supported through an unrestricted grant by TEVA Pharmaceuticals.